Investor Home

Corporate Profile

BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival...more >

Stock Quotemore >
BGNE (American Depositary Shares)

$40.88

 0.29 (0.71%)

04/28/17  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting - April 21, 2017
CAMBRIDGE, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical c... Read More
BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317 - April 21, 2017
BEIJING, April 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company de... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts